Results 151 to 160 of about 127,263 (196)

The Impact of Glucagon-Like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity. [PDF]

Cureus
Jabin A, Khan S, Khan H, Durrani ZU, Hamza K, Gul F, Atta Ullah S, Dayam F, Yaseen M, Shah S.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Physiology of Glucagon-like Peptide 1

Physiological Reviews, 2007
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed in these cells. The current knowledge regarding regulation of proglucagon gene expression in the gut and in the brain and mechanisms responsible for the ...
Jens J Holst Dmsci
openaire   +5 more sources

Glucagon-like peptide-1 and glucagon-like peptide-2

Best Practice & Research Clinical Endocrinology & Metabolism, 2004
The glucagon-like peptides (glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)) are released from enteroendocrine cells in response to nutrient ingestion. GLP-1 enhances glucose-stimulated insulin secretion and inhibits glucagon secretion, gastric emptying and feeding. GLP-1 also has proliferative, neogenic and antiapoptotic effects on
Laurie L. Baggio, Daniel J. Drucker
openaire   +1 more source

Metabolic Messengers: glucagon-like peptide 1

Nature Metabolism, 2021
Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents ...
Fiona M. Gribble, Frank Reimann
openaire   +2 more sources

Glucagon-like peptide-1 agonists

BMJ, 2012
Cannot be recommended strictly for weight reduction until their benefits and risks are ...
openaire   +2 more sources

Glucagon Like Peptide-1 and Atherosclerosis

Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012
Patients with type 2 diabetes mellitus are at high risk for developing cardiovascular diseases. Traditional medicines for type 2 diabetes, such as sulfonylureas, pioglitazone, and insulin have glucose lowering effects; however, they also increase the frequency of hypoglycemia and/or body weight and thus may cancel out the benefits of glucose lowering ...
Tomoya, Mita, Hirotaka, Watada
openaire   +2 more sources

Glucagon-like peptide-1 receptor

Current Biology
Michael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
openaire   +2 more sources